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Abstract
A twofold change in the cisplatin (DDP) sensitivity of 2008
human ovarian carcinoma cells is sufficient to reduce tumor
response in vivo. The DDP sensitivity of these cells can be
enhanced by activation of the epidermal growth factor and protein kinase C signal transduction pathways. We report here
that two endogenous growth factors, bombesin and tumor necrosis factor alpha (TNFa), enhanced DDP sensitivity by factors of 1.7±0.1 (SD)-fold and 1.8±0.1 (SD)-fold, respectively.
Both agents also produced sensitization in an 1 1-fold DDP-resistant 2008 subline. Neither bombesin nor TNFa changed the
accumulation of DDP, glutathione content, or glutathione-Stransferase activity in 2008 cells. However, a 2-h exposure to
both bombesin and TNFa was sufficient to increase 2008 cloning efficiency by up to 2.6±0.1 (SD)-fold and 2.2±0.1 (SD)fold, and it increased average colony size by 1.35±0.1 (SD)fold and 1.55±0.1 (SD)-fold, respectively. Bombesin increased
intracellular free calcium, and this was blocked by the bombesin receptor-specific antagonist SC196, demonstrating that
2008 cells have functional bombesin receptors. These results
indicate that bombesin and TNFa can enhance sensitivity to
DDP in both DDP sensitive and resistant variants of a human
ovarian carcinoma and that both agents serve as growth factors
for this tumor. (J. Clin. Invest. 1992. 90:1436-1442.) Key
words: drug resistance * signal transduction pathway * intracellular calcium * chemotherapy * mitogenesis * growth factor

Introduction
Ligand binding to a variety ofreceptors triggers the rapid generation of inositol triphosphate and diacylglycerol leading to the
activation of protein kinase C (PKC)1 ( 1 ). Bombesin, a tetraAddress correspondence and reprint requests to Stephen B. Howell,
M.D., Department of Medicine, 0812, University of California, San
Diego, La Jolla, CA 92093.
Receivedfor publication 28 November 1990 and in revisedform 13
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1. Abbreviations used in this paper: (Ca2 )i, intracellular free calcium;
DDP, cis-diamminedichloroplatinum(II); [3H]DEP, cis-dichloro([3H]-ethylenediamine)-platinum(II); EGF, epidermal growth factor; GST, glutathione-S-transferase; mCB, monochlorobimane; PKC,
protein kinase C; TNFa, tumor necrosis factor-alpha; TPA, 12-O-tetradecanoylphorbol- I 3-acetate.
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decapeptide originally isolated from frog skin (2), has been
shown to act as a mitogen for Swiss 3T3 fibroblasts (3) and
human small cell lung carcinomas (4). This peptide also has
potent pharmacological effects on pancreatic cells (5) and
elicits the release of other peptide hormones such as insulin.
Since the administration ofthis hormone stimulates the release
of other peptides, it is difficult to obtain evidence for a direct
biological activity of bombesin. In Swiss 3T3 cells, high affinity
receptors specific for this peptide have been demonstrated (6),
and bombesin is able to directly activate PKC (7). There is also
indirect evidence that bombesin can activate PKC in human
tumor cells based on its ability to generate inositol triphosphates and increase intracellular free calcium [(Ca2+)i] (5, 8).
Tumor necrosis factor-a (TNFa), secreted by macrophages (9), is a cytokine with a wide range of regulatory actions
on immune responses, inflammation, cell growth, and differentiation (10). TNFa has been reported to enhance the cytotoxicity of cis-diamminedichloro-platinum(II) (DDP) in vitro
to a human stomach adenocarcinoma ( 1) and a human ovarian carcinoma cell line ( 12 ). In contrast, TNFa does not demonstrate an actual synergistic effect when combined with DDP
in a human bladder transitional cell carcinoma in vivo ( 13).
Furthermore, when TNFa was administered for the treatment
of intraperitoneal ovarian cancer xenografts, although it prolonged survival in tumor-bearing mice (10), it also promoted
the establishment of multiple subperitoneal tumors. Like 12O-tetradecanoyl-phorbol-l 3-acetate (TPA), TNFa activates
PKC in some cell types and this in turn may result in increased
AP-l activity and induction of AP-l-responsive genes ( 14).
This is considered to be a key mechanism mediating at least
some of the biological effects of TNFa mentioned above.
We have previously reported that TPA activation of PKC
increased DDP sensitivity by a factor of 2.5-fold in human
ovarian carcinoma 2008 cells ( 15). Likewise, epidermal
growth factor (EGF), another potent activator of PKC, enhances DDP sensitivity by 3. 1-fold in the same cell line ( 16).
We report here that bombesin and TNFa, two endogenous
ligands whose receptors have the potential of activating PKC,
are also potent modulators of DDP sensitivity in 2008 cells
and, moreover, are both mitogenic for this tumor.
Methods
Materials. Bombesin was purchased from Sigma Chemical Co. (St.
Louis, MO). TNFa was purchased from Sigma Chemical Co. and
Knoll Pharmaceuticals (Whippany, NJ). DDP was obtained from the
Drug Synthesis and Chemistry Branch, Division of Cancer Treatment,
National Cancer Institute (Bethesda, MD). Monochlorobimane
(mCB) was purchased from Molecular Probes, Inc. (Eugene, OR). A
stock solution of mCB was prepared in ethanol (20 mM) and was kept
at 0-5°C, protected from light. cis-Dichloro([3H]-ethylenediamine)-
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platinum(II) ([3H]DEP) (specific activity . 16.4 (mCi/mmol), an
analog of DDP that produces adducts at identical sites in DNA, was
synthesized as previously reported ( 17 ).
Tumor cell lines. The human cell line 2008 was established from a
patient with a serious cystadenocarcinoma of the ovary ( 18 ). A resistant subline, designated 2008/C13*5, was obtained by 13 monthly
selections with 1 MM DDP followed by chronic exposure to DDP increased stepwise to 5 MM ( 19). The cells were grown on tissue culture
dishes in a humidified incubator at 370C in a 5% CO2 atmosphere.
They were maintained in medium consisting of RPMI 1640 supplemented with 5% heat inactivated fetal calf serum, 2 mM glutamine,
100 U/ml penicillin, and 100 Ag/ml streptomycin (Irvine Scientific,
Santa Ana, CA).
Bombesin and TNFa treatment and colony assays. Colony-forming assays were used to assess the mitogenic and sensitization effects of
each factor (20). Cells, trypsinized from monolayer culture, were adjusted to a concentration of 3,750 cells/5 ml in a tissue culture tube
(Corning Glass Works, Corning Medical and Scientific, Corning, NY).
5 Ml of bombesin or TNFa stock solution was added to each tube to
produce a final concentration of 300 or 2.4 nM, respectively. 10 Jl of
DDP diluted from the stock solution was then added; control tubes
received diluent alone. Tubes were incubated in humidified 5% CO2 in
air for 2 h. Each tube was then centrifuged and the cells were resuspended in 15 ml of complete medium devoid of drugs, and 5 ml of
suspended cells were plated on 60-mm polystyrene tissue culture dishes
(Corning Glass Works) in triplicate. Plates were incubated in humidified 5% CO2 air, and after 14 d plates were fixed with methanol and
stained with Giemsa. Colonies of > 60 cells were counted macroscopically. For the measurement of colony size, the longest diameter ofeach
colony was determined microscopically in 50 colonies. Cloning efficacy under control conditions was 8%.
Cell growth rate. Cell suspensions were incubated in tissue culture
tubes with either 300 nM bombesin or 2.4 nM TNFa for 2 h in humidified 5% CO2 in air. Each tube was then centrifuged and the resuspended
cells were seeded at low density in the absence ofbombesin or TNFa (2
X 104/well) in 24-well plates (Corning Glass Works). Cells were harvested at various time points and counted by hemocytometer.
[3H]DEP accumulation. Subconfluent monolayers of 2008 cells
were treated with 37°C RPMI 1640 medium containing 5 uCi/ml
[ 3H ] DEP and 5 MM cold DEP for 2 h. The medium was then aspirated,
and the cells were washed rapidly with 4°C PBS four times. 1 ml of 1 N
NaOH was added and the cells were allowed to digest overnight. A
25-Ml aliquot was used for determination of protein content by the
method of Bradford (21); 800 Ml was used for liquid-scintillation
counting.
GSH content and glutathione-S-transferase (GST) activity. GSH
content was measured by adjusting cells to 106/ ml and staining them
with 25 MM mCB in complete medium at room temperature for the
indicated time; relative cellular fluorescence was then immediately
measured on a flow cytometer (Cytofluorograph lIs; Ortho Diagnostic
Systems Inc., Raritan, NJ) with excitation and emission settings of 385
and 480 nm, respectively. Values were converted from log fluorescence
to linear fluorescence intensity by application of the equation x
= 1 0[(Y-20)/W6 where x is the relative linear fluorescent intensity and y is
the mean log channel number. Cells that were nonviable on the basis of
forward and right-angle light scatter were excluded from analysis. The
forward rate constant for the conjugation of mCB by GST is given by
the equation Kf = initial rate/[mCB] [GSH]. Since the GSH content
in the unstimulated and stimulated state turned out to be the same, and
the mCB concentration was identical, the effects of bombesin and
TNFa induction on Kf could be estimated from their effects on the
initial slope of the conjugation curve.
DNA adduct formation. Confluent monolayers growing in complete RPMI in 150 cm2 culture flasks (Corning Glass Works) underwent a medium change and were then incubated at 370C for 2 h with
10 MCi/ml [3H] DEP concurrently with either 300 nM bombesin or 2.4
nM TNFa. Cells were harvested by trypsinization, washed twice with
ice-cold PBS, and then resuspended in 0.8 ml of 100 mM NaCl, 10mM

Tris-Cl, pH 8.0; 25 mM EDTA; 0.5% SDS; 0.1 mg/ml proteinase K,
and digested at 50'C for 18 h with shaking. This was followed by extraction with phenol/chloroform, and the DNA was redissolved in 10
mM Tris-Cl pH 8.0, 1 mM EDTA containing 0.1 mg/ml RNase A and
digested at 370C for 3 h. After another extraction with phenol/chloroform, the DNA was precipitated with 70% ethanol and stored at
-70'C. The platinated DNA was digested to deoxyribonucleosides and
specific DNA-bound adducts were separated by HPLC (22). The peak
height of deoxycytosine measured at 254 nm during elution was converted to nanomoles by comparison with a standard curve. The level of
DNA platination was then expressed as dpm associated with the intrastrand guanine-guanine adduct/nmol deoxycytosine.
Cell cycle phase distribution. 1 x 106 log phase cells were exposed to
bombesin or TNFa for 2 h while growing as a monolayer, after which
the medium was replaced. Cells were harvested by trypsinization at 24,
48, and 72 h after exposure, fixed with ice-cold 70% ethanol, and then
resuspended at 106 cells/ml in PBS containing 50 MM propidium iodide and 1,000 U/ml RNase A and incubated for 30 min at 370 before
being analyzed on a flow cytometer(CytoFluorograph; Ortho Diagnostics Systems, Inc.). The fraction of cells in each phase was determined
using Multicycle Cell Cycle Software (Phoenix Flow Systems, San
Diego, CA).
(Ca2"), release. Cells were loaded over 30 min with 5 MM of the
fluorescent (Ca2+)i probe FURA2/AM (Calbiochem, San Diego, CA)
in NaCl Ringer's solution maintained at 37°C and pH 7.4 by aeration
using a 95% 02 5% CO2 gas mixture. Loaded cells were then placed
onto a glass coverslip that had previously been coated with 5 mg/ml
poly-L-lysine (Sigma Chemical Co.). The coverslip was then briefly
rinsed in NaCl, removing any remaining extracellular dye but leaving a
number of cells attached to the poly-L-lysine coating, and then was
attached with high vacuum grease to a donut-shaped glass tube, creating a chamber in which the cell-coated coverslip served as the floor.
The glass-tubing wall of the chamber circulated heated water, and thus
the NaCl added to the chamber to bathe the cells, again aerated to pH
7.4, was maintained at 37°C. This chamber was placed on an inverted
microscope (Nikon Diaphot; Nikon Corp., Melville, NY), which was
fiberoptically connected to a spectrofluorometer (SPEX AR-CM
DM3000; SPEX Industries Inc., Edison, NJ). For each experiment, a
small group (5-10) of loaded cells was selected and alternately excited
at 340 nm and 380 nm while fluorescent emissions were measured at
505 nm. Initially, emissions were measured while the cells were being
bathed in NaCl. After 60-120 s, 300 nM bombesin was added to the
bath and scanning continued. Approximately 2 min later, 25 MM ofthe
calcium ionophore ionomycin (Sigma Chemical Co.) was added to the
solution, followed in 60 s by the addition of 60-120 mM of the
calcium-chelating agent, EGTA (Sigma Chemical Co.). These last two
additions were necessary for calibration of the FURA dye emissions to
calculate (Ca2+)i levels using the Grynkiewicz Equation (23). Emission intensities from 2008 cells that were not loaded with the fluorescent probe were similarly recorded, and these measured "autofluorescent" emissions were subtracted from measured intensities emitted by
the loaded cells before calculating (Ca2+)i concentrations.
In a second set of experiments, identically loaded 2008 cells were
exposed for 15 min to 30 MM SC196, Ac-Met-Tyr-Pro-Arg-Gly-AsnHis-Trp-Ala-Val-Gly-His-LeufLeu-NH2 (a generous gift of Drs. John
Steward and Lajos Gere, UCHSC, Denver, CO), a highly specific bombesin-receptor antagonist (24), before excitation. Initially, cells were
excited while being bathed in NaCl plus 30 MM SC 196. Bombesin 300
nM was added to the physiologic solution after 2 min. The ratio of
340:380 nm emission intensities was calculated to determine whether
changes in (Ca2+)i concentrations occurred in response to the addition
of bombesin.
-

Results

Effect of bombesin and TNFa on DDP sensitivity. Fig. I (left)
shows that when 2008 cells were exposed concurrently for 2 h
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Figure 1. Sensitivity of 2008 cells to DDP in the presence (closed circles) or absence (open circles) of growth factors. Cells were treated as
follows: (left) 2,!h exposure to DDP concurrently with 300 nM bornbesin; (right) 2 h exposure to DDP concurrently with 2.4 nM TNFa.
DDP cytotoxicity was determined by clonogenic assay. Data points
represent mean values of three experiments performed with triplicate
cultures; bars represent SD.

to 300 nM bombesin and DDP, and then both agents were
removed from the cultures during the period of colony formation, bombesin increased DDP sensitivity. The IC50 in the absence ofbombesin was 4.50±1.0 ,uM (SD), whereas in the presence of bombesin it was 2.67±0.21 jM (SD). Thus, bombesin
produced a 1.7-fold increase in sensitivity (n = 3; P < 0.01).
Likewise, the Fig. 1 (right) shows that when 2008 cells were
exposed concurrently for 2 h to 2.4 nM TNFa and DDP,
TNFa increased DDP sensitivity. The IC50 in the presence of
TNFa was 2.57±0.29 ,uM (SD). Thus, TNFa produced a 1.8fold increase in sensitivity (n = 3; P < 0.01). Both bombesin
and TNFa at concentrations even up to 10 and 120 ,uM did not
cause any toxicity by themselves; thus, the interaction between
bombesin and TNFa and DDP was truly synergistic as defined
by median effect analysis (25).
Enhancement of sensitivity in DDP-resistant cells. The
2008/C13*5 cell line is 11-fold resistant to DDP. Fig. 2 (left)
shows that when these cells were exposed for 2 h concurrently
to bombesin and DDP, the IC50 was reduced from 39.0 to 21.5
,uM. The 1.6±0.3 (SD)-fold sensitization, quantitated by
change in the slope of linear portion of these dose-response
curves, was nearly identical to the 1.7-fold sensitization observed in the DDP-sensitive 2008 cells (n = 3; P < 0.01 ). Similarly, Fig. 2 (right) shows that when cells were exposed for 2 h
concurrently to TNFa and DDP, the IC50 was reduced to 22.5
,M. The 1.6±0.9 (SD)-fold sensitization, quantitated by
change in the slope of these curves, was likewise nearly identical to the 1.8-fold sensitization observed in the DDP-sensitive
2008 cells (n = 3; P < 0.01). Thus we concluded that both
bombesin and TNFa increased DDP sensitivity as effectively
in DDP-resistant as in DDP-sensitive variants of 2008.
Effect of bombesin and TNFa on cellular accumulation of
[3H]DEP. The 2008 cells were treated concurrently with
[3H] DEP and either bombesin or TNFa for 2 h. A vehicle
control consisting of an appropriate dilution of saline was run
concurrently. Neither the bombesin nor the TNFa produced
any effect on cellular accumulation of [3H ] DEP. Cells treated
with saline contained 41.1±0.3 (SD) pmol/mg protein,
whereas those treated with the bombesin contained 38.4±2.2
(SD) pmol/mg protein and those treated with TNFa con1438

tained 38.5±0.1 (SD) pmol/mg protein. Thus, bombesin and
TNFa altered DDP sensitivity by a mechanism that does not
involve an increased amount of drug entering the cell.
Effect ofbombesin and TNFa on cellular GSH content and
the activity of GST. mCB reacts quantitatively with GSH via
GST to form a fluorescent product readily quantitated by flow
cytometry. 2008 cells were stained with 25 gM mCB for
various periods of time and relative fluorescence was determined immediately by flow cytometry. Maximum staining was
obtained by 50 min, and this staining time was used for comparison of GSH content. GSH content of bombesin-treated cells
was 103±10% (SD; n = 3) of that in the untreated cells; the
relative GSH content of TNFa-treated cells was 96.5±2% (SD;
n = 3). Thus, bombesin and TNFa did not alter GSH content
significantly. Since there was no difference in GSH content, the
initial rate of reaction between GSH and mCB can be used to
estimate the rate constant for the GST-mediated reaction of
mCB with GSH, assuming that mCB has equal access to the
GSH in both cell types. GST activity in the presence of bombesin was 96.7±8.3% (SD) of that in the untreated cells; in the
case of TNFa it was 103.6±8.9% (SD). Thus, bombesin and
TNFa did not produce a significant change in GST when activity was assayed in this manner.
Effect of bombesin and TNFa on platinum DNA adduct
formation. Intrastrand DNA cross-link formation can be quantitated using [3H ] DEP as reported by Eastman ( 17 ). This technique specifically permits quantitation of the most abundant
adduct, the guanine-guanine intrastrand cross-link. [3H] DEP
DNA adduct formation in bombesin or TNFa-treated 2008
cells was 110.7±27.47 (SD) and 128.33±15.14 (SD) dpm/
nmol deoxycytosine, whereas it was 108.7±6.03 (SD) in untreated control cells. Thus, despite increasing DDP sensitivity,
bombesin and TNFa did not cause any significant increase in
DNA intrastrand cross-link formation.
Dose-dependent effect ofbombesin and TNFa on clonogenicity of 2008 cells. Fig. 3 shows the effect of a 2-h exposure to
bombesin (top) and TNFa (bottom) on the subsequent cloning
efficiency of 2008 cells. Bombesin increased the cloning effilu I
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Figure 2. The effect of bombesin and TNFa on the DDP sensitivity of
DDP-resistant cells. Cl 3*5 cells were treated with various concentrations of DDP in the presence (closed circles) or absence (open circles)
of 300 nM bombesin (left) or 2.4 nM TNFa (right) for 2 h. DDP
cytotoxicity was determined by clonogenic assay on plastic dishes.
Data points are mean values of three experiments performed with
triplicate cultures; bars represent SD.
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and TNFa on 2008
cloning efficiency. Cells
were treated as follows:
(top) 2-h drug exposure
to bombesin at various
concentrations from 10
nM to 10 MM; (bottom)
2-h drug exposure to
TNFa at various concentrations from 0.12
to 120 nM. Data points
represent the mean of
two experiments performed with triplicate
cultures; bars represent
SD (where greater than
symbol size).

cacy in a dose-dependent fashion with the maximum of
262±6% (SD) of control being attained at a concentration of 4
,uM (n = 2; P < 0.01 ). Similarly, TNFa increased clonogenicity
in a dose-dependent fashion, producing a maximum of
221 ±11% (SD) relative to control at a concentration of 12 nM
(n = 2; P < 0.01), after which a plateau was observed. Thus
both bombesin and TNFa enhanced the cloning efficacy of
2008 cells with the maximum effect of bombesin being greater
than that of TNFa.
Effect of bombesin and TNFa on colony-size distribution.
Fig. 4 shows the colony-size distribution of control 2008 cells
(top) or 2008 cells treated with either 300 nM bombesin (middle) or 2.4 nM TNFa (bottom) for 2 h and then washed before
plating. In this experiment cells were cultured for 15 d after
treatment with bombesin or TNFa to obtain larger colonies.
Both bombesin and TNFa shifted the frequency histogram to
the right. The average colony diameter in the control case was

1.20±0.26 mm (SD), whereas after treatment with bombesin it
was 1.70±0.40 mm (SD), an increase of 1.42-fold (n = 45; P
< 0.01 ). Similarly, the mean colony size after treatment with
TNFa was 2.01±0.55 mm (SD), an increase of 1.68-fold (n
-45;P<0.01).
It should be noted that both bombesin and TNFa increased
the range of colony sizes. For the control cultures size ranged
from 0.6 to 1.7 mm, whereas it ranged from 1.0 to 2.85 mm
after exposure to bombesin and from 1.3 to 4.0 mm after exposure to TNFa. Thus the coefficient of variation in colony size
after treatment with either bombesin or TNFa was larger than
control.
Dose dependence of the effect of bombesin and TNFa on
colony size. Table I shows that, like the effect on cloning efficiency, the effect of bombesin and TNFa on mean colony size
was also concentration dependent. Despite the small size ofthe
colonies in these experiments (cells were incubated for 10 d
after drug treatment) compared with the data presented above,
bombesin significantly increased the colony size at each dose
level (n = 20; P < 0.01), and the maximum colony size was
observed at a bombesin concentration of 400 nM. Similarly,
TNFa significantly increased the colony size in each dose level
(n = 20; P < 0.01), and the maximum colony size was observed at a TNFa concentration of 4.0 nM. The maximum
increase in mean colony size with bombesin was 1.36±0.07
(SD)-fold, whereas it was somewhat larger at 2.04±0.10 (SD)fold with TNFa (n = 20; P < 0.01 ).
Effect of bombesin and TNFa on growth rate of2008 cells.
An increase in apparent cloning efficiency and mean colony
size is most readily explained by an increase in cell-doubling
rate. Bombesin 300 nM and TNFa 2.4 nM increased the exponential growth-rate constant of 2008 cells by a factor of
1.09±0.01 (SD) and 1.15±0.01 (SD), (P< 0.01, ttest), respectively. Although bombesin and TNFa had equivalent mitogenic effects on 2008 cells with regard to growth rate at the
concentrations used, neither agent altered the level of the
plateau phase of growth (data not shown).
A further demonstration of the mitogenic effect of bombesin and TNFa is shown in Fig. 5. Cells were treated with a
single 2-h exposure to 300 nM bombesin or 2.4 nM TNFa,
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ter.

IP<

Bombesin

Concentration

Colony size*

nM

MM

0
100
400
4000
0
0.4
4.0
40.0

0.76±0.05

0.84±0.04*
1.04±0.05*
0.90±0.05*
0.76±0.05

1.01±0.06*
1.55±0.08*

1.55±0.04*§

Fold
increase*

1.00
1.10±0.06
1.36±0.07
1.18±0.07
1.00
1.32±0.07
2.04±0.10
2.03±0.05

* Mean±SD.
* P < 0.01 relative to control.
0.01 relative to 400 mM bombesin.
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the starting parent culture has no effect on final DDP cell survival.

Discussion
The finding that bombesin induces activation of PKC (7) and
the wide distribution of endogenous mammalian analogs of
bombesin (26) suggest that this peptide may play

washed, and the cell cycle phase distribution determined by
flow cytometry at 24-h intervals for 3 d. Both agents produced
an increase in the fraction of cells in S phase at the expense of
GI phase by 24 h (P < 0.05 for both). After exposure to TNFa
this cell-cycle phase perturbation returned to normal by 48 h;
the response was more prolonged with bombesin, requiring 72
h to return to baseline. Control cells, which were plated at the
same density as bombesin- and TNFa-treated cells, showed no
perturbation of the cell cycle phase distribution during the

72-h

observation period. This indicates that during the experiment
the cells remained in log phase growth. These results indicate
that the effect of a 2-h exposure to bombesin and TNFa on
cloning efficiency and colony size can be accounted for by a
direct mitogenic effect on cell proliferation.
(Ca2+)i release. To demonstrate the presence of functional
bombesin-specific receptors on 2008 cells, the effect of bombesin on (Ca2+ )i was measured in the presence and absence ofthe
bombesin-specific antagonist SCl 96. When grown in 5% bovine calf serum, 300 nM bombesin increased (Ca2+)i in 8% of
the cells, whereas when grown in 5% fetal calf serum, or when
serum starved for 24 h, bombesin increased (Ca2+)i in 50 and
100% of 2008 cells, respectively. In cells grown in fetal calf
serum and then serum starved for 24 h, the basal (Ca2+)i varied
between 63 and 284 nM. Bombesin increased (Ca2+)i concentration by 1.13- 1.68-fold in 100% of 60 cells examined. A typical example of this response to 300 nM bombesin is shown in
Fig. 6, which also shows that the bombesin-specific antagonist
SC196 completely blocked the ability of 300 nM to elevate
(Ca2+). This blockade was observed in 100% of the 60 cells
examined.
Effect of cell density on DDP sensitivity. Fig. 7 shows that
there is no difference between cells grown in different densities
with respect to DDP sensitivity. In both cases ICse for 1 h of
DDP exposure was 1.5 MM. It is obvious that the confluency of
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an

important

role in controlling the phenotype of both normal and malignant cells. Such a role has already been established for TNFa,
which is also capable ofactivating PKC in some cell types (14).
The first major finding resulting from the studies reported
here was that the signal transduction pathways activated by
both bombesin and TNFa can modulate the sensitivity of the
human ovarian carcinoma cell line 2008 to DDP, the most
clinically important drug for the treatment ofthis malignancy.
The effect was produced by exposure to growth factor forjust 2
h, indicating that enhancement of sensitivity was the result of
the triggering of a cascade of events initiated by ligand binding
rather than a mechanism that required the continuous presence of exogenous ligand. Other investigators have also found
that TNFa will modulate DDP sensitivity in a human ovarian
carcinoma (12) and a gastric adenocarcinoma (11) cell line,
but the ability of bombesin to enhance sensitivity to DDP has
not been reported previously. Bombesin and TNFa thus join a
rapidly growing list of receptor ligands and other signal transduction pathway activators that modulate DDP sensitivity in
2008 cells. We have previously reported that brief exposure to
EGF (16), activation of the PKC pathway with TPA (15), or
activation of the protein kinase A pathway with forskolin (27)
all enhance DDP sensitivity to varying degrees. Although the
magnitude of the modulation produced by all of these activators is relatively small (1.6-3.2-fold), levels of resistance as
small as 2.5-fold produce clearly reduced response to DDP
treatment in vivo when the 2008 cells are grown as a xenograft
(28). Irrespective ofwhether such modulation is clinically relevant, the ability of these factors to enhance sensitivity in the
2008 cells provides an additional approach to understanding
the mechanism by which cells defend themselves against this
chemotherapeutic agent.
The major mechanisms mediating resistance to DDP include impairment of drug uptake, elevated levels of GSH or
metallothioneins, or enhanced DNA repair (for review see ref-
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EGF concentration and receptor number ( 16). However, sensitivity to bombesin and TNFa is largely determined at the postreceptor level (6, 7, 30), and such a relationship may not per-
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29). The mechanism by which signal transduction acti-

vators modulate DDP sensitivity

appears to vary. In the case of
activation of the protein kinase A pathway, the major effect is
an increase in DDP uptake (27), whereas activation of the
EGF receptor or PKC does not alter uptake ( 15, 16). Bombesin and TNFa were selected for study because they are possible
endogenous activators of PKC (9, 26). Like TPA they failed to
enhance DDP uptake, produced no change in GSH content or
apparent GST activity, and did not alter the number of intrastrand cross-links formed. It is unlikely that enhancement of
DDP sensitivity is mediated by a decrease in metallothioneins
since these are relatively stable proteins with cellular half-lives
of many hours ( 15) whereas the sensitization response was
observed by 2 h. No information is yet available on the effect of
either TPA or bombesin and TNFa on the ability of 2008 cells

to

remove

DDP adducts from DNA, and the mechanism of the

bombesin and TNFa effect on DDP sensitivity remains to be
determined. It is also noteworthy that, like TPA (15) but unlike EGF (16), bombesin and TNFa were able to modulate
DDP sensitivity in both the DDP-sensitive and -resistant variants of 2008. In the case of EGF, we have been able to show
that ability to modulate DDP sensitivity is a function of both

tain to either of these factors.
The second major finding to emerge from these studies was
that both bombesin and TNFa are mitogenic for human ovarian carcinoma 2008 cells. Although TNFa is cytotoxic to many
types of tumors in vitro and in vivo, against 2008 cells it produced an effect similar to that of bombesin in stimulating cloning efficiency, colony size, and growth rate. Although the number of cell-surface receptors for bombesin and TNFa were not
determined, these data clearly indicate the existence of physiologically significant numbers of receptor types responsive to
both factors.
A direct mitogenic effect of bombesin has been reported for
several other cells types, including small cell carcinomas (4)
and Swiss 3T3 fibroblasts. Swiss 3T3 cells exhibit large numbers of receptors for a variety of growth factors, including bombesin (31 ), and a mitogenic effect was observed using a bombesin concentration only 3% of that needed by the 2008 cells. A
mitogenic response to TNFa was reported also for human astrocytoma cells (32); although receptor number was not quantitated, the concentration of TNFa at which the effect was observed was well within the concentration range needed to produce a response in 2008 cells.
It is of interest that the mitogenic effect of bombesin and
TNFa was very prolonged. A 2-h exposure to either agent followed by washing of the cells was sufficient to commit the 2008
cells to a change in growth rate that was still apparent 24-48 h
later, and a change in the size of colonies produced that was
detectable 15 d later. We have reported this same sort of response with EGF, where a brief exposure was sufficient to commit the 2008 cells to an altered colony morphology that was
still present 10-14 d later (16). We speculate that the effects of
bombesin and TNFa on the growth of 2008 cells may be indirect, and that brief exposure to either may be initiating the
production of an autocrine growth factor that either produces
and maintains the alteration in cytokinetics or potentiates such
effects of factors already present in the culture medium. It is
important to emphasize that the ability of bombesin and TNFa
to enhance DDP sensitivity may not be linked to their mitogenic effects; these may be entirely independent effects of receptor activation.
The concentration of bombesin causing mitogenesis in
2008 cells was substantially higher (maximum effect 4,000
nM) than that required for mitogenesis in Swiss 3T3 (33) or
human small cell lung carcinoma lines (34) cells, raising the
question of whether bombesin was working via another receptor. However, the studies with Swiss 3T3 and nonsmall cell
lung cancer cells lines used continuous exposure to bombesin
or gastrin-releasing peptide, whereas the dose-response curve
depicted in Fig. 3 was obtained using only a 2-h exposure.
Moreover, the ability of the bombesin receptor-specific inhibitor SC 196 to block the bombesin-induced increase in (Ca2+ )
established that the 2008 cells do contain bona fide bombesin
receptors but not that this receptor type is responsible for the
mitogenic or sensitizing response. These cells may also contain
neuromedian B receptors, and it is possible that both receptor
types may contribute to the mitogenic or sensitizing responses
or that bombesin is producing these responses indirectly via
another growth factor that is less effective on 2008 than the
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other cell types. Because of the toxicity of SC 196 to 2008 cells it
has not been possible to establish that blockade of the bombesin receptors can inhibit the bombesin-induced increase in
DDP sensitivity or proliferation rate.
Interest in TNFa as a potential regulator of DDP sensitivity
and/or tumor growth in human ovarian carcinoma is heightened by reports that a significant fraction of these tumors appear to produce TNF (35) and that TNF treatment of several
human ovarian carcinoma xenografts increases their local invasiveness ( 10). TNFa is currently being tested in the United
States as a treatment for ovarian carcinoma. Both our results
and those of other investigators ( 10, 35, 36) suggest the need
for caution and careful assessment of whether TNFa might be
detrimental to such patients.
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